<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="194398">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00561080</url>
  </required_header>
  <id_info>
    <org_study_id>V211-043</org_study_id>
    <secondary_id>X06-Z-305</secondary_id>
    <nct_id>NCT00561080</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of a 1-dose Regimen of a Zoster Vaccine Versus Different 2-dose Regimens in Subjects ≥ 70 Years</brief_title>
  <official_title>An Open-label, Randomised, Comparative, Multi-centre Study of the Immunogenicity and Safety of a 1-dose Regimen and Different 2-dose Regimens of a Zoster Vaccine (Live), ZOSTAVAX ®, in Subjects ≥ 70 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      Primary objective:

      Immunogenicity To demonstrate that a second dose of ZOSTAVAX® elicits higher
      varicella-zoster virus (VZV) antibody titres than a first dose of ZOSTAVAX® whether given as
      a 0-1 month schedule or as a 0-3 month schedule in subjects ≥70 years of age as measured at
      4 weeks post-vaccination

      Secondary objectives Immunogenicity

        -  To summarise the VZV antibody titres at 4 weeks post-vaccination after a 1-dose regimen
           and 4 weeks post-vaccination after each dose of each 2-doses regimen of ZOSTAVAX®.

        -  To compare the VZV antibody titres at 12 months after completion of a 1-dose regimen
           with the VZV antibody titres at 12 months after completion of each 2-doses regimen of
           ZOSTAVAX®

        -  To summarise the VZV antibody titres at 24 and 36 months after completion of a 1-dose
           regimen and at 24 and 36 months after completion of each 2-doses regimen of ZOSTAVAX®
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The 4 weeks post-dose 1 and 4 weeks post-dose 2 VZV antibody titres in group 2 and in group 3</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The 4 weeks post-dose 1 VZV antibody titres in group 1</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The VZV antibody titres individual fold rise from pre-vaccination to 4 weeks post-dose 1 in all groups and 4 weeks post-dose 2 in group 2 and in group 3</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The 12 months post-dose 1 VZV antibody titres in group 1 and the 12 months post-dose 2 VZV antibody titres in group 2 and in group 3</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The VZV antibody titres individual fold rise from pre-vaccination to 12 months post-dose 1 in group 1 and from pre-vaccination to 12 months post-dose 2 in group 2 and in group 3</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The 24 and 36 months post-dose 1 VZV antibody titres in group 1 and the 24 and 36 months post-dose 2 VZV antibody titres in group 2 and in group 3</measure>
    <time_frame>24 and 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The VZV antibody titres individual fold rise from pre-vaccination to 24 and 36 months post-dose 1 in group 1 and from pre-vaccination to 24 and 36 months post-dose 2 in group 2 and in group 3</measure>
    <time_frame>24 and 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Injection site erythema; Injection site swelling; Injection site pain</measure>
    <time_frame>Day 0 to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unsolicited injection-site adverse reactions; Herpes zoster/ varicella/ zoster-like rash/ varicella-like rash; Other systemic adverse events; Any serious adverse events</measure>
    <time_frame>Day 0 to Day 28 following each vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deaths; Vaccine-related serious adverse events; Herpes zoster/ zoster-like rash</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Prevention of : Herpes-Zoster</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Zostavax</intervention_name>
    <description>One dose (0.65 mL)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Zostavax</intervention_name>
    <description>Two doses (0.65 mL) at one month interval</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Zostavax</intervention_name>
    <description>Two doses (0.65 mL) at 3 months interval</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 70 years

          2. Varicella history-positive or residence for &gt; 30 years in a country with endemic VZV
             infection

          3. Signed informed consent form prior to any study procedure

        Exclusion Criteria:

          1. Febrile illness within the last 72 hours before the first vaccination

          2. Prior herpes-zoster episode clinically diagnosed by a physician

          3. Prior receipt of varicella or zoster vaccine

          4. Exposure to varicella or herpes-zoster within the 4 weeks prior to the first
             vaccination

          5. Significant underlying illness preventing completion of the study vaccination
             schedules,

          6. Known active tuberculosis,

          7. Immune deficiency disorder, including active neoplastic disease within the prior 5
             years,

          8. Immune function impairment caused by medical condition or immunosuppressive therapy,
             or any other cause,

          9. Receipt of any inactivated vaccine within the 2 weeks prior to the first vaccination,

         10. Receipt of any other live vaccine within the 4 weeks prior to the first vaccination,

         11. Receipt of immunoglobulins or blood-derived products within the 5 months prior to the
             first vaccination,

         12. Concomitant use of non-topical antiviral therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Fiquet, MD</last_name>
    <role>Study Director</role>
    <affiliation>SPMSD</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Järvenpää</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kotka</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vantaa</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dülmen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Großheirath-Rossach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haag</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heilbronn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ingelheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Künzing</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nettersheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Schwerin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Straubing</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiavari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ragusa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taranto</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>DC Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albacete</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospitalet de Llobregat</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Getxo</name>
      <address>
        <city>Pais Vasco</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vigo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 13, 2017</lastchanged_date>
  <firstreceived_date>November 19, 2007</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
